Drug intelligence / Profile preview

PPMX-T003

Development stage: Phase 2
Lead developer: Perseus Proteomics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PPMX-T003 is a fully human monoclonal antibody targeting transferrin receptor 1 (TfR1), developed by Perseus Proteomics. It is designed to inhibit iron uptake by cells that highly express TfR1, such as erythroblasts and certain cancer cell lines. The drug acts through antibody-dependent cell cytotoxicity and direct antagonism of TfR1, leading to suppression of erythrocyte differentiation and inhibition of cancer cell growth. Its primary indications include polycythemia vera and aggressive NK-cell leukemia[2][3][9].

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on PPMX-T003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPMX-T003.

Explore the full profile